Dianthus Therapeutics (DNTH) EBITDA (2017 - 2025)

Dianthus Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$36.7 million for Q3 2025.

• In Q3 2025, EBITDA fell 50.07% year-over-year to -$36.7 million; the TTM figure through Sep 2025 stood at -$126.9 million (down 91.04% YoY), while the FY2024 annual figure was -$84.9 million, down 95.88% from the prior year.
• EBITDA was -$36.7 million for Q3 2025 at Dianthus Therapeutics, down from -$31.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$7.0 million in Q1 2023 to a low of -$36.7 million in Q3 2025.
• Historically, EBITDA has averaged -$18.7 million across 5 years, with a median of -$17.4 million in 2021.
• The sharpest annual moves came in 2023 and 2024: EBITDA soared 70.14% in 2023, then sank 176.02% in 2024.
• A 5-year view of EBITDA shows it stood at -$19.3 million in 2021, then surged by 47.59% to -$10.1 million in 2022, then declined by 3.8% to -$10.5 million in 2023, then sank by 176.02% to -$29.0 million in 2024, then fell by 26.49% to -$36.7 million in 2025.
• The last three EBITDA figures came in at -$36.7 million (Q3 2025), -$31.8 million (Q2 2025), and -$29.3 million (Q1 2025), per Business Quant data.